Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 1.00 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 1.00 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 1.00 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.64 |
| ▸ | RELA | Q04206 | 1/20 | 0.64 |
| ▸ | NQO1 | P15559 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29401747 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8651660 | 0.88 | MAPT (0.78) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL31238099 | 0.88 | MEN1 (0.78) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL13940470 | 0.87 | MAPT (0.77) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8656092 | 0.87 | MAPT (0.77) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL10506584 | 0.84 | MAPT (0.71) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL10506975 | 0.84 | ALDH1A1 (0.71) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL10504983 | 0.84 | MAPT (0.71) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8368653 | 0.83 | MAPT (0.70) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8656023 | 0.81 | MAPT (0.68) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016040650-A1 | SOLUBLE GUANYLYL CYCLASE INHIBITION EFFECTS ON LYMPHATIC VASCULATURE | UNIVERSITY OF ROCHESTER (US) | 2016-03-17 | — | — | WO | claimed |
| US-8026217-B2 | Compositions and methods for treating neural anoxia and spreading depression | FLORIDA ATLANTIC UNIVERSITY (US) | 2011-09-27 | — | — | US | claimed |
| US-7858579-B2 | Thermoprotective compositions of pkg pathway inhibitors and method of use thereof | DAWSON-SCULLY KENNETH | 2010-12-28 | — | — | US | claimed |
| US-20090124558-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURAL ANOXIA AND SPREADING DEPRESSION | FLORIDA ATLANTIC UNIVERSITY (US) | 2009-05-14 | — | — | US | claimed |
| WO-2009046322-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURAL ANOXIA AND SPREADING DEPRESSION | FLORIDA ATLANTIC UNIVERSITY (US) | 2009-04-09 | — | — | WO | claimed |
| WO-2008076370-A9 | P21 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HIV | GEN HOSPITAL CORP (US) | 2008-08-21 | — | — | WO | claimed |
| WO-2008076370-A2 | P21 COMPOSITIONS AND METHODS FOR THE TREATMENT OF HIV | THE GENERAL HOSPITAL CORPORATION (US) | 2008-06-26 | — | — | WO | claimed |
| US-20070184044-A1 | Thermoprotective compositions of PKG pathway inhibitors and method of use thereof | DAWSON-SCULLY KENNETH | 2007-08-09 | — | — | US | claimed |
| US-20060194769-A1 | Small molecules that reduce fungal growth | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-31 | — | — | US | claimed |
| WO-2006081327-A2 | SMALL MOLECULES THAT REDUCE FUNGAL GROWTH | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2006-08-03 | — | — | WO | claimed |
| WO-2004098601-A1 | AS A PKC INHIBITOR, INHIBITOR FOR ANGIOGENESIS CONTAINING 6-ANILINOQUINOLINE-5,8-QUINONE AS AN EFFECTIVE INGREDIENT | CHEMON INC. (KR) | 2004-11-18 | — | — | WO | claimed |
| EP-1451211-A2 | COMPOSITIONS AND METHODS FOR MODULATING GUANYLYL CYCLASE SIGNALING RECEPTOR (GC-C) ACTIVITY AND FOR TREATING MENIERE'S DISEASE | University of Copenhagen (DK) | 2004-09-01 | — | — | EP | claimed |
| US-20040152868-A1 | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease | UNIVERSITY OF COPENHAGEN (DK) | 2004-08-05 | — | — | US | claimed |
| EP-1398031-A1 | Use of 6-amino-quinoline-5,8-quinones and nucleic acids associated with senescence for the treatment of tumors | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2004-03-17 | — | — | EP | claimed |
| WO-2002079235-A2 | COMPOSITIONS AND METHODS FOR MODULATING GUANYLYL CYCLASE SIGNALING RECEPTOR (GC-C) ACTIVITY AND FOR TREATING MENIERE'S DISEASE | UNIVERSITY OF COPENHAGEN (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2000030630-A1 | COMBINATION PRODUCTS OF A GUANYLATE CYCLASE INHIBITOR AND A LOCAL ANESTHETIC FOR PAIN RELIEF | LINDEN BIOTECHNOLOGY, INC. (US) | 2000-06-02 | — | — | WO | claimed |
| EP-0866692-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA Société Anonyme (FR) | 1998-09-30 | — | — | EP | claimed |
| WO-1997021432-A1 | USE OF BICYCLIC MONO- OR DIKETONE DERIVATIVES, RESULTING COMPOUNDS, AND USE THEREOF AS A DRUG FOR TREATING INFLAMMATION, MIGRAINE AND SHOCK | LABORATOIRE INNOTHERA, S.A. (FR) | 1997-06-19 | — | — | WO | claimed |
| US-5298506-A | Use of guanylate cyclase inhibitors in the treatment of shock | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1994-03-29 | — | — | US | claimed |
| US-4492704-A | ANTHISTAMINES | ELI LILLY AND COMPANY (US) | 1985-01-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194769-A1 | Small molecules that reduce fungal growth | ERG28, DPM1, CYP51A1 | MAPT 1481/4885SMN1; SMN2 4868/4885ALDH1A1 2931/4885 |
| US-20040152868-A1 | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease | PDE7A, PDE6C, PDE9A | MAPT 4187/4885SMN1; SMN2 2367/4885ALDH1A1 4193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.